Amphastar Pharmaceuticals Inc (AMPH) reports robust sales growth in key products and strategic pipeline expansions, despite facing increased competition and profitability pressures.

Viatris Inc. (Nasdaq: VTRS) today reported strong third quarter 2025 financial results and updated full-year financial ...

Additionally, Viatris received approval from the U.S. Food and Drug Administration for its Iron Sucrose Injection, USP, marking the first generic version of Venofer Injection. This intravenous product ...

Additionally, the U.S. Food and Drug Administration approved Viatris’ Iron Sucrose Injection, USP, marking the first generic version of Venofer Injection. This intravenous iron replacement product is ...

Amphastar Pharmaceuticals Inc ( ($AMPH) ) has released its Q3 earnings. Here is a breakdown of the information Amphastar Pharmaceuticals Inc ...

The FDA has approved a once-monthly injection of Eli Lilly’s Omvoh for maintenance therapy in adult patients with moderately ...

The FDA approved an intravenous (IV) formulation of fosfomycin (Contepo) to treat adults with complicated urinary tract ...

IVTherapyTrend and #hydrationtherapy, and #wellnessdrip all point toward intravenous infusions of fluids, vitamins, minerals and other compounds, in what' ...

The FDA is requiring updated labeling for tranexamic acid injection to emphasize the risk of serious harm, including death, if administered incorrectly via spinal injection. Tranexamic acid injection ...

After Hurricane Helene knocked out a North Carolina plant that supplies much of the IV fluid hospitals depend upon, MUSC ...